Supplement encyclopedia

Bifidobacterium breve

Bifidobacterium breve is a species of bifidobacteria found in some probiotic supplements and specially fortified foods. B-3, 207-1, M-16V, MCC1274, and DSM32583 are distinct strains. Supplements may contain live cells in capsules or powders.

Double-check the conclusions and review the sources before choosing a supplement.

Main conclusion

Potential benefits

  • CCFM1025 may improve perceived sleep quality in adults with stress-related insomnia. Over four weeks, the sleep questionnaire score decreased by an average of 3.85 points versus 1.45 with placebo.
  • Live B-3 may slightly reduce fat mass in adults with elevated fat mass. In one trial over 12 weeks, it decreased by about 0.53 kg more than with placebo.
  • In another study of adults with a BMI of 25–30, the difference in fat mass change over 12 weeks was about 0.6 kg in favor of B-3: fat mass remained close to baseline with the supplement but increased with placebo.
  • In adults with irritable bowel syndrome and diarrhea, Bif195 showed no convincing advantage in the overall intestinal symptom score over eight weeks.
  • In adults with sarcopenia, heat-inactivated B-3 showed no convincing advantage in knee extension strength over 24 weeks.

[1] [2] [3] [4] [5]

What was studied

  • In adults aged 50–79 with suspected mild cognitive impairment, MCC1274/A1 improved the overall memory and thinking test result compared with placebo after 16 weeks.
  • In women aged 30–79, M-16V showed no convincing advantage in the overall skin condition assessment from images or in self-rated skin condition.
  • Gas and temporary digestive symptoms are possible. With severe illness, immunodeficiency, or premature infants, the choice of a live probiotic requires an individual medical assessment.

[1] [2] [3] [4]

Forms studied

  • Two body-composition studies used live B-3 at 5 or 20 billion CFU daily for 12 weeks. The sarcopenia study used a different form of B-3: 20 billion heat-inactivated cells daily for 24 weeks.
  • The sleep study used CCFM1025 sachets with maltodextrin for four weeks. When choosing a product, check the full strain code and the carrier’s composition.
  • On the label, look for the full strain code, CFU count at the end of shelf life, and storage conditions. Inactivated cell counts are listed separately from live CFU.

[1] [2] [3] [4] [5]

How to get it from food

  • The fermented milk studied contained B. breve strain Yakult together with other cultures and galactooligosaccharides. This is the composition of a specific mixture.
  • Strain DSM32583 was studied in a separate formula for full-term infants. Check the label for the composition and strain in a particular food product.

[1] [2] [3]

Effects and studied questions

How to read the certainty scale 1–4

Certainty is rated separately for each outcome. 1 is very low, 2 is low, 3 is moderate and 4 is high.

Goal or questionResultConfidenceStudiesPopulation studiedKey sources
Overall symptom severity in IBS with diarrhea — Bif195No significant advantage was found on the overall IBS symptom scale. Scores changed by −43.3 versus −38.2 points. The small sample does not rule out an effect.
2/4 LowPrecision of the estimate. Small sample, lack of a confidence interval, or a substantial number of missing outcomes. Consistency across studies. Different strains and products do not independently replicate the same result. Inconsistency cannot be assessed for this specific combination of participants, intervention, comparator, and outcome. The original assessment applied no additional downgrade on this basis (0 levels). Applicability to the specified group. Direct evidence for the specified participants, strain, and outcome. Potential publication bias. There are too few direct studies to assess publication bias. The original assessment applied no additional downgrade on this basis (0 levels). Risk of bias. One small randomized study. Uncertainties about group allocation and reporting, along with missing outcomes, reduce confidence.
11 publication describedEight weeks of treatment with probiotic Bifidobacterium breve, Bif195 lowers fatigue scores in patients with diarrhoea-predominant irritable bowel syndrome: results from a randomised, clinical trial ↗61 adults with diarrhea-predominant IBS, 52 included in the analysis
  1. Eight weeks of treatment with probiotic Bifidobacterium breve, Bif195 lowers fatigue scores in patients with diarrhoea-predominant irritable bowel syndrome: results from a randomised, clinical trial ↗
Antibiotic-associated diarrhea in children — PRL2020Diarrhea was reported in 6/71 versus 14/50 participants who completed the study. In the control group, 21 of 71 participants dropped out, so the true magnitude of the effect is highly uncertain.
1/4 Very lowPrecision of the estimate. Small sample, lack of a confidence interval, or a substantial number of missing outcomes. Consistency across studies. Different strains and products do not independently replicate the same result. Inconsistency cannot be assessed for this specific combination of participants, intervention, comparator, and outcome. The original assessment applied no additional downgrade on this basis (0 levels). Applicability to the specified group. Direct evidence for the specified participants, strain, and outcome. Potential publication bias. There are too few direct studies to assess publication bias. The original assessment applied no additional downgrade on this basis (0 levels). Risk of bias. The outcome was assessed without blinding, and attrition was very uneven between groups after randomization. The missing results could substantially change the direction of the effect.
11 publication describedBifidobacterium breve PRL2020 mitigates antibiotic-induced gut symptoms and dysbiosis in children treated with amoxicillin or amoxicillin-clavulanate ↗142 children aged 3–12 taking amoxicillin or amoxicillin with clavulanate, 121 completed the study
  1. Bifidobacterium breve PRL2020 mitigates antibiotic-induced gut symptoms and dysbiosis in children treated with amoxicillin or amoxicillin-clavulanate ↗
Cognitive tests in people with suspected mild impairment — MCC1274/A1At week 16, the adjusted RBANS total cognitive test score was 11.3 points higher than with placebo (95% confidence interval 6.7–15.8). This finding concerns adults with suspected mild cognitive impairment.
2/4 LowPrecision of the estimate. One study with 80 participants. The confidence interval of 6.7–15.8 RBANS points allows for substantially different magnitudes of improvement. Independent replication is limited. Consistency across studies. Different strains and products do not independently replicate the same result. Inconsistency cannot be assessed for this specific combination of participants, intervention, comparator, and outcome. The original assessment applied no additional downgrade on this basis (0 levels). Applicability to the specified group. The stated target group is people with suspected mild cognitive impairment. The conclusion does not extend to healthy people or dementia prevention. Potential publication bias. There are too few direct studies to assess publication bias. The original assessment applied no additional downgrade on this basis (0 levels). Risk of bias. There is uncertainty about the reporting of this particular study and the relevance of the result to everyday functioning. The data pertain to a group with impairments.
11 publication describedProbiotic Bifidobacterium breve in Improving Cognitive Functions of Older Adults with Suspected Mild Cognitive Impairment: A Randomized, Double-Blind, Placebo-Controlled Trial ↗80 adults aged 50–79 with suspected mild cognitive impairment, 79 completed the study
  1. Probiotic Bifidobacterium breve in Improving Cognitive Functions of Older Adults with Suspected Mild Cognitive Impairment: A Randomized, Double-Blind, Placebo-Controlled Trial ↗

The study count refers to the cited source. Reviews with overlapping trials and outcomes from one study are not added together.

Forms

Live Bif195, PRL2020, MCC1274/A1, CCFM1025, and M-16V: These are distinct strains. The results cards specify the different doses, durations, and participant groups. The name B. breve alone is insufficient to identify an equivalent product. In the sleep study, CCFM1025 was given in sachets with maltodextrin. The exact dose cannot be determined from the paper. Live and inactivated B-3: For body composition, live B-3 was studied at doses of 5 or 20 billion CFU/day. The sarcopenia study used 20 billion heat-inactivated cells/day. Nonliving cells do not count as viable CFU. Food formulations: The fermented milk with the Yakult strain also contained other cultures and a prebiotic. DSM32583 was included in a separate infant formula. The presence of B. breve does not make different food formulations and single-strain cultures interchangeable.

Guidance for each goal

Overall symptom severity in IBS with diarrhea — Bif1952/4 LowRead moreCollapse
Confidence
2/4 LowPrecision of the estimate. Small sample, lack of a confidence interval, or a substantial number of missing outcomes. Consistency across studies. Different strains and products do not independently replicate the same result. Inconsistency cannot be assessed for this specific combination of participants, intervention, comparator, and outcome. The original assessment applied no additional downgrade on this basis (0 levels). Applicability to the specified group. Direct evidence for the specified participants, strain, and outcome. Potential publication bias. There are too few direct studies to assess publication bias. The original assessment applied no additional downgrade on this basis (0 levels). Risk of bias. One small randomized study. Uncertainties about group allocation and reporting, along with missing outcomes, reduce confidence.

No significant advantage was found on the overall IBS symptom scale. Scores changed by −43.3 versus −38.2 points. The small sample does not rule out an effect.

Study findings. No significant advantage was found on the overall IBS symptom scale. Scores changed by −43.3 versus −38.2 points. The small sample does not rule out an effect.

Studied regimenAt least 15 billion CFU/dayB. breve Bif195 (DSM 33360), a live oral probiotic
Duration and population8 weeks61 adults with diarrhea-predominant IBS, 52 included in the analysis

Comparator — placebo

Antibiotic-associated diarrhea in children — PRL20201/4 Very lowRead moreCollapse
Confidence
1/4 Very lowPrecision of the estimate. Small sample, lack of a confidence interval, or a substantial number of missing outcomes. Consistency across studies. Different strains and products do not independently replicate the same result. Inconsistency cannot be assessed for this specific combination of participants, intervention, comparator, and outcome. The original assessment applied no additional downgrade on this basis (0 levels). Applicability to the specified group. Direct evidence for the specified participants, strain, and outcome. Potential publication bias. There are too few direct studies to assess publication bias. The original assessment applied no additional downgrade on this basis (0 levels). Risk of bias. The outcome was assessed without blinding, and attrition was very uneven between groups after randomization. The missing results could substantially change the direction of the effect.

Diarrhea was reported in 6/71 versus 14/50 participants who completed the study. In the control group, 21 of 71 participants dropped out, so the true magnitude of the effect is highly uncertain.

Study findings. Diarrhea was reported in 6/71 versus 14/50 participants who completed the study. In the control group, 21 of 71 participants dropped out, so the true magnitude of the effect is highly uncertain.

Studied regimen20 billion live cells per dose, twice dailyB. breve PRL2020, a live oral probiotic
Duration and populationFor the duration of the antibiotic course142 children aged 3–12 taking amoxicillin or amoxicillin with clavulanate, 121 completed the study

Comparator — usual care without a probiotic. No placebo was used.

Cognitive tests in people with suspected mild impairment — MCC1274/A12/4 LowRead moreCollapse
Confidence
2/4 LowPrecision of the estimate. One study with 80 participants. The confidence interval of 6.7–15.8 RBANS points allows for substantially different magnitudes of improvement. Independent replication is limited. Consistency across studies. Different strains and products do not independently replicate the same result. Inconsistency cannot be assessed for this specific combination of participants, intervention, comparator, and outcome. The original assessment applied no additional downgrade on this basis (0 levels). Applicability to the specified group. The stated target group is people with suspected mild cognitive impairment. The conclusion does not extend to healthy people or dementia prevention. Potential publication bias. There are too few direct studies to assess publication bias. The original assessment applied no additional downgrade on this basis (0 levels). Risk of bias. There is uncertainty about the reporting of this particular study and the relevance of the result to everyday functioning. The data pertain to a group with impairments.

At week 16, the adjusted RBANS total cognitive test score was 11.3 points higher than with placebo (95% confidence interval 6.7–15.8). This finding concerns adults with suspected mild cognitive impairment.

Study findings. At week 16, the adjusted RBANS total cognitive test score was 11.3 points higher than with placebo (95% confidence interval 6.7–15.8). This finding concerns adults with suspected mild cognitive impairment.

Studied regimen20 billion CFU/dayB. breve MCC1274/A1, a live oral probiotic
Duration and population16 weeks80 adults aged 50–79 with suspected mild cognitive impairment, 79 completed the study

Comparator — placebo

Subjective sleep quality — CCFM10251/4 Very lowRead moreCollapse
Confidence
1/4 Very lowPrecision of the estimate: A small sample or the absence of a confidence interval leaves uncertainty. Consistency across studies: Inconsistency in results for this specific strain and outcome has not been established. The original assessment applied no additional downgrade on this basis (0 levels). Applicability to the specified group: The result applies only to the specified strain, dose, participants, and outcome. Possible publication bias: There are too few studies to assess publication bias, and there is no direct evidence of missing studies. The original assessment applied no additional downgrade on this basis (0 levels). Risk of bias: The study has noted limitations involving participant selection, reporting, or missing data.

Over 4 weeks, the mean Pittsburgh Sleep Quality Index (PSQI) score decreased by 3.85 points with CCFM1025 and by 1.45 points with placebo. The simple difference in changes was −2.40 points.

Study findings. Over 4 weeks, the mean Pittsburgh Sleep Quality Index (PSQI) score decreased by 3.85 points with CCFM1025 and by 1.45 points with placebo. The simple difference in changes was −2.40 points.

Studied regimenThe exact dose is unknown. The abstract lists 5 billion CFU, while the methods section lists 1 billion CFU per daySachet containing B. breve CCFM1025 and maltodextrin
Duration and population4 weeks40 adults aged 18–65 with stress-related insomnia and a baseline PSQI score above 7

Comparator: Placebo: sachet containing only maltodextrin

Fat mass in the first trial — B-32/4 LowRead moreCollapse
Confidence
2/4 LowPrecision of the estimate: A small sample or the absence of a confidence interval leaves uncertainty. Consistency across studies: Inconsistency in results for this specific strain and outcome has not been established. The original assessment applied no additional downgrade on this basis (0 levels). Applicability to the specified group: The result applies only to the specified strain, dose, participants, and outcome. Possible publication bias: There are too few studies to assess publication bias, and there is no direct evidence of missing studies. The original assessment applied no additional downgrade on this basis (0 levels). Risk of bias: The study has noted limitations involving participant selection, reporting, or missing data.

Over 12 weeks, the change in fat mass differed between groups by about 0.6 kg in favor of B-3 (p=0.03 after adjustment for baseline values). The graph shows that fat mass stayed near baseline with B-3 and increased with placebo.

Study findings. Over 12 weeks, the change in fat mass differed between groups by about 0.6 kg in favor of B-3 (p=0.03 after adjustment for baseline values). The graph shows that fat mass stayed near baseline with B-3 and increased with placebo.

Studied regimen20 billion CFU/dayB. breve B-3
Duration and population12 weeks80 adults with a BMI of 25–30, predominantly men

Comparator — placebo

DXA-measured fat mass in the second trial — B-32/4 LowRead moreCollapse
Confidence
2/4 LowPrecision of the estimate: A small sample or the absence of a confidence interval leaves uncertainty. Consistency across studies: Inconsistency in results for this specific strain and outcome has not been established. The original assessment applied no additional downgrade on this basis (0 levels). Applicability to the specified group: The result applies only to the specified strain, dose, participants, and outcome. Possible publication bias: There are too few studies to assess publication bias, and there is no direct evidence of missing studies. The original assessment applied no additional downgrade on this basis (0 levels). Risk of bias: The study has noted limitations involving participant selection, reporting, or missing data.

In another study, fat mass changed by −587 g versus −64 g, with an adjusted difference of about −529 g.

Study findings. In another study, fat mass changed by −587 g versus −64 g, with an adjusted difference of about −529 g.

Studied regimen5 billion CFU/dayB. breve B-3
Duration and population12 weeks83 adults with elevated fat mass in the per-protocol analysis

Comparator — placebo

Total body weight — B-32/4 LowRead moreCollapse
Confidence
2/4 LowPrecision of the estimate: A small sample or the absence of a confidence interval leaves uncertainty. Consistency across studies: Inconsistency in results for this specific strain and outcome has not been established. The original assessment applied no additional downgrade on this basis (0 levels). Applicability to the specified group: The result applies only to the specified strain, dose, participants, and outcome. Possible publication bias: There are too few studies to assess publication bias, and there is no direct evidence of missing studies. The original assessment applied no additional downgrade on this basis (0 levels). Risk of bias: The study has noted limitations involving participant selection, reporting, or missing data.

In the 2022 study, the authors reported that by week 12, total body weight was lower in the B-3 group than in the placebo group. The exact difference in weight could not be confirmed from the available data.

Study findings. In the 2022 study, the authors reported that by week 12, total body weight was lower in the B-3 group than in the placebo group. The exact difference in weight could not be confirmed from the available data.

Studied regimen5 billion CFU/dayB. breve B-3
Duration and population12 weeksAdults with elevated fat mass in the 2022 B-3 trial

Comparator — placebo

Knee extension strength in sarcopenia — inactivated B-32/4 LowRead moreCollapse
Confidence
2/4 LowPrecision of the estimate. Small sample, lack of a confidence interval, or a substantial number of missing outcomes. Consistency across studies. Different strains and products do not independently replicate the same result. Inconsistency cannot be assessed for this specific combination of participants, intervention, comparator, and outcome. The original assessment applied no additional downgrade on this basis (0 levels). Applicability to the specified group. Direct evidence for the specified participants, strain, and outcome. Potential publication bias. There are too few direct studies to assess publication bias. The original assessment applied no additional downgrade on this basis (0 levels). Risk of bias. One small randomized study. Uncertainties about group allocation and reporting, along with missing outcomes, reduce confidence.

After 24 weeks, the between-group difference in the change in knee extension strength was +0.55 kgf (95% confidence interval −1.10 to +2.10 kgf, p=0.554). No statistically significant benefit was found.

Study findings. After 24 weeks, the between-group difference in the change in knee extension strength was +0.55 kgf (95% confidence interval −1.10 to +2.10 kgf, p=0.554). No statistically significant benefit was found.

Studied regimen20 billion heat-inactivated cells/dayB. breve B-3 — heat-inactivated preparation
Duration and population24 weeks50 adults aged 50–89 years with sarcopenia were enrolled, and 49 were included in the analysis. By week 24, strength data were available for 43 participants.

Comparator — placebo

Brown skin spots assessed by imaging — M-16V2/4 LowRead moreCollapse
Confidence
2/4 LowPrecision of the estimate: A small sample or the absence of a confidence interval leaves uncertainty. Consistency across studies: Inconsistency in results for this specific strain and outcome has not been established. The original assessment applied no additional downgrade on this basis (0 levels). Applicability to the specified group: The result applies only to the specified strain, dose, participants, and outcome. Possible publication bias: There are too few studies to assess publication bias, and there is no direct evidence of missing studies. The original assessment applied no additional downgrade on this basis (0 levels). Risk of bias: The study has noted limitations involving participant selection, reporting, or missing data.

Image analysis showed that the median change in the brown spot score was −1.00 versus −0.05 at week 4 (p=0.013) and −0.50 versus −0.06 at week 8 (p=0.041). Whether the difference was noticeable in everyday life was not assessed.

Study findings. Image analysis showed that the median change in the brown spot score was −1.00 versus −0.05 at week 4 (p=0.013) and −0.50 versus −0.06 at week 8 (p=0.041). Whether the difference was noticeable in everyday life was not assessed.

Studied regimen20 billion CFU/dayB. breve M-16V — live oral probiotic
Duration and population12 weeks120 Japanese women aged 30–79

Comparator — placebo

Overall skin score assessed by imaging — M-16V2/4 LowRead moreCollapse
Confidence
2/4 LowPrecision of the estimate: A small sample or the absence of a confidence interval leaves uncertainty. Consistency across studies: Inconsistency in results for this specific strain and outcome has not been established. The original assessment applied no additional downgrade on this basis (0 levels). Applicability to the specified group: The result applies only to the specified strain, dose, participants, and outcome. Possible publication bias: There are too few studies to assess publication bias, and there is no direct evidence of missing studies. The original assessment applied no additional downgrade on this basis (0 levels). Risk of bias: The study has noted limitations involving participant selection, reporting, or missing data.

Worsening within the placebo group alone does not establish an improvement in the primary VISIA measure. The abstract did not establish a between-group benefit.

Study findings. Worsening within the placebo group alone does not establish an improvement in the primary VISIA measure. The abstract did not establish a between-group benefit.

Studied regimen20 billion CFU/dayB. breve M-16V — live oral probiotic
Duration and population12 weeks120 Japanese women aged 30–79

Comparator — placebo

Self-rated skin condition — M-16V2/4 LowRead moreCollapse
Confidence
2/4 LowPrecision of the estimate. Small sample, lack of a confidence interval, or a substantial number of missing outcomes. Consistency across studies. Different strains and products do not independently replicate the same result. Inconsistency cannot be assessed for this specific combination of participants, intervention, comparator, and outcome. The original assessment applied no additional downgrade on this basis (0 levels). Applicability to the specified group. Direct evidence for the specified participants, strain, and outcome. Potential publication bias. There are too few direct studies to assess publication bias. The original assessment applied no additional downgrade on this basis (0 levels). Risk of bias. One small randomized study. Uncertainties about group allocation and reporting, along with missing outcomes, reduce confidence.

Self-reported measures of skin condition improved in both groups, with no statistically significant difference between them.

Study findings. Self-reported measures of skin condition improved in both groups, with no statistically significant difference between them.

Studied regimen20 billion CFU/dayB. breve M-16V — live oral probiotic
Duration and population12 weeks120 healthy women aged 30–79

Comparator — placebo

Safety and limitations

Gas and temporary digestive symptoms may occur. In the 2022 B-3 trial, adverse events were reported in 15 of 51 participants receiving B-3 and 14 of 49 receiving placebo. The most common events occurred after COVID-19 vaccination. The authors assessed the remaining events as mild and unrelated to the study product. No serious events were recorded. In a small Bif195 study in people with IBS, two events were judged to be related to the product: abdominal pain and rash. If a rash develops, stop taking the product and have the reaction assessed. This observation does not establish how often these events occur with other strains. Use of a live product requires an individual medical assessment for people with severe illness or immunodeficiency and for preterm infants. The FDA report describes a B. longum infection in a preterm infant. It does not establish a B. breve infection. Data from adults do not establish a regimen for use during pregnancy or breastfeeding, or in children. Match the exact strain, live or inactivated form, dose, and viability through the end of the product’s shelf life. If you have a food allergy, check the ingredients in the carrier. Short studies cannot rule out rare or delayed complications.

Probiotics — Health Professional Fact Sheet (NIH ODS) ↗ · Body Fat Reduction Effect of Bifidobacterium breve B-3: A Randomized, Double-Blind, Placebo Comparative Clinical Trial ↗ · Eight weeks of treatment with probiotic Bifidobacterium breve, Bif195 lowers fatigue scores in patients with diarrhoea-predominant irritable bowel syndrome: results from a randomised, clinical trial ↗ · Risk of Invasive Disease in Preterm Infants Given Probiotics Formulated to Contain Live Bacteria or Yeast (FDA) ↗

Food sources

Food composition

FoodGroupAmountServingCaloriesSources
Fermented milk with the Yakult strain and GOSStudied mixture of live cultures and galactooligosaccharidesFermented milk drinks—In the original study, B. breve strain Yakult was part of a dairy product that also contained a prebiotic and other cultures. The species was confirmed in this formulation. The effect of the mixture cannot be attributed to B. breve alone.——Consecutive Intake of Fermented Milk Containing Bifidobacterium breve Strain Yakult and Galacto-oligosaccharides Benefits Skin Condition in Healthy Adult Women ↗
Infant formula with DSM32583Studied formula for full-term infantsSpecialized infant nutrition—In the trial, 10⁷ CFU of DSM32583 were added per gram of formula. This is an identified food vehicle for a specific age group. It is not used to dose a supplement for adults.——Evaluation of Safety and Beneficial Health Effects of the Human-Milk Strain Bifidobacterium breve DSM32583: An Infant Pilot Trial ↗

Consecutive Intake of Fermented Milk Containing Bifidobacterium breve Strain Yakult and Galacto-oligosaccharides Benefits Skin Condition in Healthy Adult Women ↗

Studies

PublicationWhat was studiedParticipantsForm and doseResult
Eight weeks of treatment with probiotic Bifidobacterium breve, Bif195 lowers fatigue scores in patients with diarrhoea-predominant irritable bowel syndrome: results from a randomised, clinical trial ↗Overall symptom severity in IBS with diarrhea — Bif19561 adults with diarrhea-predominant IBS, 52 included in the analysisB. breve Bif195 (DSM 33360) — live oral probiotic, at least 15 billion CFU/day, 8 weeks, comparator: placeboNo significant advantage was found on the overall IBS symptom scale. Scores changed by −43.3 versus −38.2 points. The small sample does not rule out an effect.
Bifidobacterium breve PRL2020 mitigates antibiotic-induced gut symptoms and dysbiosis in children treated with amoxicillin or amoxicillin-clavulanate ↗Antibiotic-associated diarrhea in children — PRL2020142 children aged 3–12 taking amoxicillin or amoxicillin with clavulanate, 121 completed the studyB. breve PRL2020 — live oral probiotic, 20 billion live cells twice daily throughout the course of antibiotics, comparator: usual care without a probiotic. No placebo was usedDiarrhea was reported in 6/71 versus 14/50 participants who completed the study. In the control group, 21 of 71 participants dropped out, so the true magnitude of the effect is highly uncertain.

Sources

Sources
  1. Eight weeks of treatment with probiotic Bifidobacterium breve, Bif195 lowers fatigue scores in patients with diarrhoea-predominant irritable bowel syndrome: results from a randomised, clinical trial ↗
  2. Bifidobacterium breve PRL2020 mitigates antibiotic-induced gut symptoms and dysbiosis in children treated with amoxicillin or amoxicillin-clavulanate ↗
  3. Probiotic Bifidobacterium breve in Improving Cognitive Functions of Older Adults with Suspected Mild Cognitive Impairment: A Randomized, Double-Blind, Placebo-Controlled Trial ↗
  4. Bifidobacterium breve CCFM1025 Improves Sleep Quality via Regulating the Activity of the HPA Axis: A Randomized Clinical Trial ↗
  5. Effects of Bifidobacterium breve B-3 on body fat reductions in pre-obese adults: a randomized, double-blind, placebo-controlled trial ↗
  6. Body Fat Reduction Effect of Bifidobacterium breve B-3: A Randomized, Double-Blind, Placebo Comparative Clinical Trial ↗
  7. Effects of Heat-Killed Bifidobacterium breve B-3, a Postbiotic, on Muscle Mass-Related Parameters in Patients with Sarcopenia: A Randomized, Double-Blind, Placebo-Controlled Pilot Trial ↗
  8. Imaging and Microorganism Analyses of the Effects of Oral Bifidobacterium breve Intake on Facial Skin in Females: A Randomized, Double-Blind, Placebo-Controlled Study ↗
  9. Probiotics — Health Professional Fact Sheet (NIH ODS) ↗
  10. Consecutive Intake of Fermented Milk Containing Bifidobacterium breve Strain Yakult and Galacto-oligosaccharides Benefits Skin Condition in Healthy Adult Women ↗
  11. Evaluation of Safety and Beneficial Health Effects of the Human-Milk Strain Bifidobacterium breve DSM32583: An Infant Pilot Trial ↗
  12. Risk of Invasive Disease in Preterm Infants Given Probiotics Formulated to Contain Live Bacteria or Yeast (FDA) ↗